Lung Cancer ScreeningNCT07716527
Pilot Testing a Web-based Prototype of a Lung Cancer Screening Digital Health Tool
A study testing Digital health tool prototype in people with Lung Cancer Screening, run by Rutgers, The State University of New Jersey at 1 site in United States.
Trial summary
The purpose of this study is to evaluate the acceptability, usability, and preliminary efficacy of a web-based prototype of a digital health tool for lung cancer screening (LCS). The digital health tool is designed to support high quality decision-making for individuals potentially eligible for lung cancer screening. Read more about this study
- Who is it for?
- Ages 50 to 80 years
- Conditions the study is for
- Lung Cancer Screening
- What is being tested?
- Digital health tool prototype
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jun 2026to 15 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 50-80 years
- Currently smoke or have quit smoking within the past 15 years
- English-speaking
Who cannot join
- Younger than 50 years or older than 80 years
- Never smoked or quit smoking more than 50 years ago
- Non-English-speaking
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901
About this study
The purpose of this study is to evaluate the acceptability, usability, and preliminary efficacy of a web-based prototype of a digital health tool for lung cancer screening (LCS). The digital health tool is designed to support high quality decision-making for individuals potentially eligible for lung cancer screening. Researchers will compare the intervention arm (who will use the digital health tool prototype) with the control arm (who will read a 2-page publicly available information sheet about lung cancer screening from American Cancer Society).
Read the detailed description
Lung cancer is the leading cause of cancer death in the US. In 2011, the landmark National Lung Screening Trial demonstrated that LCS using low-dose computed tomography (LDCT) can reduce lung cancer mortality by 20%, compared to chest X-rays, after annual screenings. Hence, the United States Preventive Services Task Force (USPSTF) recommends LCS for individuals age 50-80, who currently smoke or quit smoking within the past 15 years, and who have at least a 20 pack-year smoking history. The USPSTF gave LCS a Grade B recommendation, indicating that there is high certainty that the benefits of LCS outweigh the risks for this population. Despite the well-documented benefits of LCS and USPSTF's Grade B recommendation, LCS uptake remains very low at only 18%. In contrast, breast and colon cancer screening rates exceed 70%, even though their combined annual deaths are ¾ that of lung cancer. As LCS has both potential benefits and harms (e.g., false positives, small amounts of radiation exposure, potential invasive diagnostic testing), USPSTF also recommends that all patients undergo shared decision-making (SDM) prior to initial screening. Furthermore, the Centers for Medicare \& Medicaid Services (CMS) mandates an SDM conversation using a decision aid prior to initial screening. Yet, SDM is not routinely performed and patients are rarely informed about potential harms in routine practice. Hence, interventions aiming to improve LCS uptake and decision quality among high-risk populations are urgently needed to realize the mortality benefit of LCS.
To address these gaps, the investigators will develop a digital health tool, which is an interactive website that delivers high-quality, standardized SDM and psychoeducation about LCS to patients. This study's aims are to: 1) evaluate acceptability of the digital health tool prototype among people with a smoking history; 2) assess changes in cognitive outcomes before and after exposure to the digital health tool and across comparison groups; and 3) assess the digital health tool's impact on LCS intentions.
The digital health tool includes a home page and 7 modules: 1) a video decision aid about LCS; 2) video of the LDCT procedure; 3) lung cancer risk calculator and individualized lung cancer risk scores for patients; 4) patient testimonials; 5) frequently asked questions (e.g., costs associated with LDCT); 6) patient's decision; and 7) resources for smoking cessation.
For this pilot study, the investigators will be utilizing a quantitative approach using surveys. This study will use a randomized pre-post design to assess the impact of exposure to the digital health tool prototype. Participants (N=500) will be randomized to view either the digital health tool prototype or standard education materials about LCS in a 1:1 ratio. Participants will be contacted 3 months after the initial survey to complete a brief follow-up survey assessing LCS behavior.
Participants will be recruited through Qualtrics Research Panels. Potential participants will complete a screening form to confirm their eligibility. The inclusion criteria are: 1) age 50-80; and 2) currently smoke or quit smoking within the past 15 years. If they are eligible, potential participants will be directed to an informed consent form where they will be asked to indicate their agreement to participate in this study. Participants who agree to participate will then complete a pre-survey, use either the digital health tool prototype or standard education materials, and then complete a post-survey. 3 months after the initial survey, participants will be contacted again to complete a follow-up survey.
- Conditions
- Lung Cancer Screening
- Being tested
- Digital health tool prototype, Control Arm - standard of care
- Keywords
- Lung cancer screening, Digital health tool, Web-based prototype, Prototype, Decision support
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital health tool prototypeBehavioural
Intervention participants will view a web-based interactive prototype of the digital health tool. The digital health tool contains information about lung cancer screening, the screening procedures, a personalized lung cancer risk calculator, patient stories, frequently asked questions, and smoking cessation resources.
Control Arm - standard of careBehavioural
The control arm will read a 2-page educational material about lung cancer screening publicly available from American Cancer Society.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Not described Receives: Behavioral: Digital health tool prototype |
| Control | Active comparator | Not described Receives: Behavioral: Control Arm - standard of care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Self- reported receipt of Lung Cancer Screening
Self-reported receipt of LCS within 3 months of exposure to the digital health tool
Measured: 3 months
Secondary outcomes (10)
Lung Cancer Screening Intention
Intention to undergo LCS in the next 3 months, measured during the post-test survey administered immediately after viewing the digital health tool. Patient will respond on a 4-point agreement scale (strongly agree/agree/disagree/strongly disagree).
Measured: Immediately post-intervention (within 24 hours)
Stage of Decision Making
Stage of decision making will be assessed using the validated single-item Stage of Decision Making Scale. The measure assesses participants' readiness to make a decision regarding lung cancer screening by asking them to select one of six statements describing their current stage of decision making, ranging from not yet thinking about the decision to having made a decision and being unlikely to change their mind. Responses are coded on a 6-point ordinal scale, with higher scores indicating greater readiness or progression toward making a decision.
Measured: Immediately post-intervention (within 24 hours)
Ottowa Acceptability Measure
Acceptability will be assessed using the 10-item validated Ottawa Acceptability of Decision Aid Measure. The Ottawa Acceptability Measure has 8 items evaluating each section of the digital health tool (4-point Likert scale ranging from Poor to Excellent), length of presentation (too short/too long/just right), amount of information (too much/too little/just right), balance (slanted towards LCS/not slanted towards LCS/balanced), usefulness of the website (yes/no), risk calculation understanding (easy/difficult), and enough information (yes/no). The measure also includes two open-ended questions regarding what participants liked about the website and suggested improvements.
Measured: Immediately post-intervention (within 24 hours)
System Usability Scale (SUS)
Website usability will be assessed using the 10-item validated System Usability Scale (SUS). The SUS evaluates participants' overall perceptions of the usability of the digital health tool, including ease of use, complexity, consistency, confidence while using the system, and willingness to use the system frequently. Each item is rated on a 5-point Likert scale ranging from Strongly disagree to Strongly agree. After reverse scoring negatively worded items, responses are summed and converted to a 0-100 scale, with higher scores indicating better perceived usability.
Measured: Immediately post-intervention (within 24 hours)
Knowledge of LCS
Knowledge of lung cancer screening will be assessed using the 20-item Lung Cancer Screening Knowledge Measure (LCS-15). The LCS-15 evaluates participants' knowledge of lung cancer screening, including eligibility criteria, screening frequency, potential benefits and harms of low-dose computed tomography (LDCT), false-positive results, overdiagnosis, incidental findings, radiation exposure, follow-up testing, and the importance of smoking cessation. Each item is answered using correct, incorrect, or "I don't know" response options. Correct responses are scored as 1, while incorrect and "I don't know" responses are scored as 0. Item scores are summed and converted to a 0-100% score, with higher scores indicating greater knowledge of lung cancer screening.
Measured: Immediately post-intervention (within 24 hours)
Perceived risk
Perceived risk of lung cancer will be assessed using the 3-item Perceived Risk subscale of the validated Lung Cancer Screening Health Belief Scales (LCSHBS). The subscale measures participants' perceived susceptibility to developing lung cancer by assessing their perceived risk, likelihood of developing lung cancer in the next few years, and overall likelihood of developing lung cancer. Items are rated on a 4-point Likert scale ranging from Strongly disagree to Strongly agree. Responses are summed to produce a total score ranging from 3 to 12, with higher scores indicating greater perceived risk of developing lung cancer.
Measured: Immediately post-intervention (within 24 hours)
Perceived benefits
Perceived benefits of lung cancer screening will be assessed using the 6-item Perceived Benefits subscale of the validated Lung Cancer Screening Health Belief Scales (LCSHBS). The subscale evaluates participants' beliefs about the benefits of undergoing lung cancer screening with low-dose computed tomography (LDCT), including beliefs that screening can detect lung cancer early, improve treatment outcomes, and reduce the risk of dying from lung cancer. Items are rated on a 4-point Likert scale ranging from Strongly disagree to Strongly agree. Responses are summed to produce a total score ranging from 6 to 24, with higher scores indicating stronger perceived benefits of lung cancer screening.
Measured: Immediately post-intervention (within 24 hours)
Perceived barriers
Perceived barriers to lung cancer screening will be assessed using the 17-item Perceived Barriers subscale of the validated Lung Cancer Screening Health Belief Scales (LCSHBS). The subscale assesses participants' perceived emotional, practical, and logistical barriers to completing lung cancer screening, including concerns about cost, fear, time, transportation, inconvenience, and access. Items are rated on a 4-point Likert scale ranging from Strongly disagree to Strongly agree. Responses are summed to produce a total score ranging from 17 to 68, with higher scores indicating greater perceived barriers to lung cancer screening.
Measured: Immediately post-intervention (within 24 hours)
Decisional Conflict (SURE)
Decisional conflict will be assessed using the 4-item validated SURE Test. The SURE Test evaluates whether participants feel certain about the best choice, understand the benefits and risks of available options, are clear about which benefits and risks matter most to them, and have sufficient support and advice to make a decision. Items are answered using Yes/No response options. Responses are summed to produce a total score ranging from 0 to 4, with higher scores indicating less decisional conflict and greater confidence in decision making.
Measured: Immediately post-intervention (within 24 hours)
Preparation for Decision Making
Preparation for decision making will be assessed using the 10-item validated Preparation for Decision Making Scale (PrepDM). The PrepDM measures the extent to which the digital health tool prepares participants to communicate with their healthcare provider and make an informed decision about lung cancer screening. Items assess whether the tool helped participants recognize that a decision needs to be made, understand the benefits and harms of screening, clarify what matters most to them, organize their thoughts, identify questions for their healthcare provider, and prepare to discuss their preferences and make a decision. Each item is rated on a 5-point Likert scale ranging from Not at all to A great deal. Item scores are averaged and transformed to a 0-100 scale, with higher scores indicating greater perceived preparation for decision making.
Measured: Immediately post-intervention (within 24 hours)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2026
- Study start1 Jun 2026
- Primary completion15 Oct 2026 (estimated)
- Study completion15 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rutgers, The State University of New Jersey
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Naomi Tan, PhD, Rutgers, The State University of New Jersey
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07716527
- Sponsor's protocol ID
- Pro2026000388
- Status last verified
- Jul 2026
- First submitted
- 30 Jun 2026
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: As this study represents a prototype phase of tool development, the underlying data are not being made publicly available at this time. The data will be used to inform ongoing refinement and validation of the digital health tool prior to broader dissemination.
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Testing a Web-based Prototype of a Lung Cancer Screening Digital Health Tool
- ClinicalTrials.gov ID
- NCT07716527
- Acronym / sponsor ID
- Pro2026000388
- Conditions
- Lung Cancer Screening
- Keywords
- Lung cancer screening, Digital health tool, Web-based prototype, Prototype, Decision support
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Rutgers, The State University of New JerseyUniversity, hospital or other
- Study start
- 1 Jun 2026 (actual)
- Primary completion
- 15 Oct 2026 (estimated)
- Study completion
- 15 Oct 2026 (estimated)
- First posted
- 21 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the acceptability, usability, and preliminary efficacy of a web-based prototype of a digital health tool for lung cancer screening (LCS). The digital health tool is designed to support high quality decision-making for individuals potentially eligible for lung cancer screening. Researchers will compare the intervention arm (who will use the digital health tool prototype) with the control arm (who will read a 2-page publicly available information sheet about lung cancer screening from American Cancer Society).
Detailed description
Lung cancer is the leading cause of cancer death in the US. In 2011, the landmark National Lung Screening Trial demonstrated that LCS using low-dose computed tomography (LDCT) can reduce lung cancer mortality by 20%, compared to chest X-rays, after annual screenings. Hence, the United States Preventive Services Task Force (USPSTF) recommends LCS for individuals age 50-80, who currently smoke or quit smoking within the past 15 years, and who have at least a 20 pack-year smoking history. The USPSTF gave LCS a Grade B recommendation, indicating that there is high certainty that the benefits of LCS outweigh the risks for this population. Despite the well-documented benefits of LCS and USPSTF's Grade B recommendation, LCS uptake remains very low at only 18%. In contrast, breast and colon cancer screening rates exceed 70%, even though their combined annual deaths are ¾ that of lung cancer. As LCS has both potential benefits and harms (e.g., false positives, small amounts of radiation exposure, potential invasive diagnostic testing), USPSTF also recommends that all patients undergo shared decision-making (SDM) prior to initial screening. Furthermore, the Centers for Medicare \& Medicaid Services (CMS) mandates an SDM conversation using a decision aid prior to initial screening. Yet, SDM is not routinely performed and patients are rarely informed about potential harms in routine practice. Hence, interventions aiming to improve LCS uptake and decision quality among high-risk populations are urgently needed to realize the mortality benefit of LCS.
To address these gaps, the investigators will develop a digital health tool, which is an interactive website that delivers high-quality, standardized SDM and psychoeducation about LCS to patients. This study's aims are to: 1) evaluate acceptability of the digital health tool prototype among people with a smoking history; 2) assess changes in cognitive outcomes before and after exposure to the digital health tool and across comparison groups; and 3) assess the digital health tool's impact on LCS intentions.
The digital health tool includes a home page and 7 modules: 1) a video decision aid about LCS; 2) video of the LDCT procedure; 3) lung cancer risk calculator and individualized lung cancer risk scores for patients; 4) patient testimonials; 5) frequently asked questions (e.g., costs associated with LDCT); 6) patient's decision; and 7) resources for smoking cessation.
For this pilot study, the investigators will be utilizing a quantitative approach using surveys. This study will use a randomized pre-post design to assess the impact of exposure to the digital health tool prototype. Participants (N=500) will be randomized to view either the digital health tool prototype or standard education materials about LCS in a 1:1 ratio. Participants will be contacted 3 months after the initial survey to complete a brief follow-up survey assessing LCS behavior.
Participants will be recruited through Qualtrics Research Panels. Potential participants will complete a screening form to confirm their eligibility. The inclusion criteria are: 1) age 50-80; and 2) currently smoke or quit smoking within the past 15 years. If they are eligible, potential participants will be directed to an informed consent form where they will be asked to indicate their agreement to participate in this study. Participants who agree to participate will then complete a pre-survey, use either the digital health tool prototype or standard education materials, and then complete a post-survey. 3 months after the initial survey, participants will be contacted again to complete a follow-up survey.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: Digital health tool prototype |
| Control | Active comparator | Behavioral: Control Arm - standard of care |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 50-80 years
- Currently smoke or have quit smoking within the past 15 years
- English-speaking
Key exclusion criteria (3 listed)
- Younger than 50 years or older than 80 years
- Never smoked or quit smoking more than 50 years ago
- Non-English-speaking
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital health tool prototypeIntervention participants will view a web-based interactive prototype of the digital health tool. The digital health tool contains information about lung cancer screening, the screening procedures, a personalized lung cancer risk calculator, patient stories, frequently asked questions, and smoking cessation resources. | Behavioural | Intervention |
| Control Arm - standard of careThe control arm will read a 2-page educational material about lung cancer screening publicly available from American Cancer Society. | Behavioural | Control |
Primary outcome
Self- reported receipt of Lung Cancer Screening
Time frame: 3 months
Self-reported receipt of LCS within 3 months of exposure to the digital health tool
10 secondary outcomes
Lung Cancer Screening Intention
Time frame: Immediately post-intervention (within 24 hours)
Stage of Decision Making
Time frame: Immediately post-intervention (within 24 hours)
Ottowa Acceptability Measure
Time frame: Immediately post-intervention (within 24 hours)
System Usability Scale (SUS)
Time frame: Immediately post-intervention (within 24 hours)
Knowledge of LCS
Time frame: Immediately post-intervention (within 24 hours)
Perceived risk
Time frame: Immediately post-intervention (within 24 hours)
Perceived benefits
Time frame: Immediately post-intervention (within 24 hours)
Perceived barriers
Time frame: Immediately post-intervention (within 24 hours)
Decisional Conflict (SURE)
Time frame: Immediately post-intervention (within 24 hours)
Preparation for Decision Making
Time frame: Immediately post-intervention (within 24 hours)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Individual participant dataSharing planned: No. As this study represents a prototype phase of tool development, the underlying data are not being made publicly available at this time. The data will be used to inform ongoing refinement and validation of the digital health tool prior to broader dissemination.
Related trials for Lung Cancer Screening
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Not yet recruiting
Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers
Lung Cancer (Diagnosis), Smoking Cessation
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Digital health tool prototype in people with Lung Cancer Screening, run by Rutgers, The State University of New Jersey at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Self- reported receipt of Lung Cancer Screening (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.